Myrtelle Inc.
PrivateLast Round
Early Stage
VC
Jun 22, 2026
Total Funding Raised
$83.67M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Myrtelle Inc. operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series C round in December 2025.
Myrtelle Inc. is a biotechnology company that develops and delivers novel gene therapy treatments for devastating disorders of the central nervous system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Myrtelle Inc. Comparables
Compare Myrtelle Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Capsida Biotherapeutics | 81% | |
| BridgeBio Pharma, Inc. | 81% | |
| Ajinomoto Co. Inc | 80% |
For institutional investors. Book with your work email.
Myrtelle Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Stage VC | Jun 22, 2026 | ||||
| Series C | Dec 23, 2025 | ||||
| Debt | Mar 11, 2025 | ||||
| Debt | Jun 7, 2024 | ||||
| Series B | Dec 1, 2022 | ||||
Early Funding | Oct 4, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Myrtelle Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Panacea Venture Healthcare | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors grew 72% MoM, from 2.9K to 5K.
- Jun 22, 2026
$17M raised in early stage VC round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 22, 2026
Myrtelle, Inc. develops MYR-103 on an oligodendrocyte-targeting rAAV platform designed to selectively reach oligodendrocytes and suppress abnormal PLP1 overexpression; the program remains at an early or unclear clinical-development stage, with no registered interventional trial publicly documented in 2026.
For institutional investors. Book with your work email.
Myrtelle Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Myrtelle Inc.'s valuation, stock price, and market status.
Is Myrtelle Inc. a public or private company?
Myrtelle Inc. is a private company.
What is the current stock price of Myrtelle Inc.?
Myrtelle Inc. is a private company, so its shares have no public market price. Caplight tracks Myrtelle Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Myrtelle Inc. worth (valuation)?
Valuation information for Myrtelle Inc. is not publicly available.
Can I buy Myrtelle Inc. stock?
Myrtelle Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Myrtelle Inc.'s last funding round?
Myrtelle Inc.'s most recent funding round was Early Stage VC on June 22, 2026.
Who are the main investors in Myrtelle Inc.?
Key investors in Myrtelle Inc. include Panacea Venture Healthcare.
Will Myrtelle Inc. IPO soon?
No public IPO plans have been announced for Myrtelle Inc..
How can I track Myrtelle Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Myrtelle Inc.'s shares on secondary markets.